Navigation Links
Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
Date:10/12/2010

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.

At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Vincent Miller from Memorial Sloan-Kettering Cancer Center in New York, USA, reported findings from the LUX-Lung 1 trial of afatinib in 585 patients with lung adenocarcinoma whose cancer had progressed after chemotherapy and erlotinib or gefitinib.

The participants were randomly assigned to either best supportive care plus a placebo, or supportive care plus afatinib, which is an irreversible inhibitor of two cancer-associated cell surface molecules --epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).

While the results showed no significant difference in overall survival between the two groups, patients who were given afatinib saw disease progression delayed and were more likely to experience tumor shrinkage, Dr Miller said.

Median overall survival was 10.78 months for patients who received supportive care plus afatinib, compared to 11.96 months for those receiving supportive care plus placebo. "The median overall survival for both arms was expected to be approximately five months," Dr Miller said. "The fact that it was nearly one year was unexpected."

Median progression-free survival was 3.3 months for patients administered afatinib, compared to 1.1 month in the placebo group. The disease control rate after 8 weeks of therapy was 58% in the afatinib arm, and 19% for the placebo arm. The investigator analysis saw an overall response rate of 11% in afatinib patients, compared to 0.5% for those receiving placebo plus best supportive care.

"Our study showed that adding afatinib to best supportive care improved progression free but not overall survival as compared to placebo and best supportive care in patients with advanced non-small cell lung cancer who previously received chemotherapy and either gefitinib or erlotinib," Dr Miller said.

Although the trial did not achieve its primary endpoint of extending life, this does not diminish the potential value of this drug in treating patients with this most lethal cancer killer, Dr Miller said.

"The fact that afatinib induced objective regressions in a population with no or limited treatment options, delayed progression of cancer and associated with some improvement in cancer-related symptoms cannot be minimized," said Dr Miller.

"The LUX-lung 1 randomized phase III trial demonstrates that afatinib (BIBW2992) is a very active compound in NSCLC," commented Professor Jean-Charles Soria from Institut Gustave Roussy, Paris, France.

"The lack of survival benefit may be related to the likely high enrichment of the trial population by EGFR mutated patients with outstanding median survival times of around 11 months in the 3rd/4th line setting," Prof Soria added. Such survivals are unprecedented in NSCLC and simply highlight the intrinsic good prognosis of EGFR-mutated NSCLC patients.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Benefits of increased health care transparency hinge on reliable and valid information, says ACP
2. Benefits of healthy lifestyle factors stronger in combination
3. Mouse Study May Help Explain Fish Oils Benefits
4. Double-Dose Plavix Benefits Certain Patients, Study Finds
5. Research demonstrates benefits of medical cannabis as a treatment for chronic pain
6. Researchers study benefits of white button mushrooms
7. Society of Interventional Radiology advances global definition of specialty, benefits patients
8. Social Security Disability Benefits Can Be Crucial to Surviving With Spinal Cord Injury, Allsup Reports
9. Advocate Health Care Reports $462 Million in Community Benefits
10. Intensively lowering glucose: Possible benefits must be weighed against risks
11. Examining risks and benefits of alcohol consumption
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
Breaking Medicine Technology: